Literature DB >> 17631552

Test-retest reproducibility of 18F-MPPF PET in healthy humans: a reliability study.

Nicolas Costes1, Luc Zimmer, Anthonin Reilhac, Franck Lavenne, Philippe Ryvlin, Didier Le Bars.   

Abstract

UNLABELLED: The aim of this study was to assess the reliability of 2'-methoxyphenyl-(N-2'-pyridinyl)-p-18F-fluoro-benzamidoethylpiperazine (18F-MPPF) PET binding parameter's quantification via a test-retest study over a long-term period.
METHODS: Ten healthy volunteers underwent 2 dynamic 18F-MPPF PET scans in an interval of 6 mo. As a methodologic control, 10 simulated datasets, including interindividual functional and anatomic variabilities, were also used to assess the measurement variations in the absence of intraindividual variability. Indices of tracer binding were computed using 2 different models: (a) the simplified reference tissue model (SRTM) and (b) the Logan graphical model. The SRTM allows computing the binding potential (BP) index and plasma-to-brain transport constants (R1, k2). The Logan model evaluates the distribution volume (DV). For both methods, cerebellum was taken as the reference region. From both models, binding indices were calculated with time-activity curves extracted from regions of interest, on one hand, and for each voxel to perform parametric images on the other hand.
RESULTS: Reliability indices--that is, bias, variability, and intraclass correlation (ICC)--indicated a good reproducibility: the BP percentage change in mean between test and retest is close to 1% in rich regions and 2% in poor regions. The typical error is around 7%. Mean ICC is over 0.70. The DV percentage change in the mean is +/-2.5%, with a typical error close to 6% and an ICC over 0.60.
CONCLUSION: Our results show a good reliability, with a reasonable level of intraindividual biologic variability that allows crossover studies with 18F-MPPF in which small percentage changes are expected between test and retest measurements, in group studies and for single subject assessment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17631552     DOI: 10.2967/jnumed.107.041905

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  9 in total

1.  MicroPET imaging of 5-HT 1A receptors in rat brain: a test-retest [18F]MPPF study.

Authors:  Nicolas Aznavour; Chawki Benkelfat; Paul Gravel; Antonio Aliaga; Pedro Rosa-Neto; Barry Bedell; Luc Zimmer; Laurent Descarries
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-15       Impact factor: 9.236

2.  Switching brain serotonin with oxytocin.

Authors:  Raphaelle Mottolese; Jérôme Redouté; Nicolas Costes; Didier Le Bars; Angela Sirigu
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

3.  Reproducibility and reliability of anti-3-[¹⁸F]FACBC uptake measurements in background structures and malignant lesions on follow-up PET-CT in prostate carcinoma: an exploratory analysis.

Authors:  Oluwaseun A Odewole; Oyeladun A Oyenuga; Funmilayo Tade; Bital Savir-Baruch; Peter T Nieh; Viraj Master; Zhengjia Chen; Xiaojing Wang; Ashesh B Jani; Leah M Bellamy; Raghuveer K Halkar; Mark M Goodman; David M Schuster
Journal:  Mol Imaging Biol       Date:  2015-04       Impact factor: 3.488

Review 4.  5-HT radioligands for human brain imaging with PET and SPECT.

Authors:  Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen
Journal:  Med Res Rev       Date:  2011-06-14       Impact factor: 12.944

5.  18F-Mefway PET imaging of serotonin 1A receptors in humans: a comparison with 18F-FCWAY.

Authors:  Jae Yong Choi; Chul Hyoung Lyoo; Jin Su Kim; Kyeong Min Kim; Jee Hae Kang; Soo-Hee Choi; Jae-Jin Kim; Young Hoon Ryu
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

6.  Social behavioral changes in MPTP-treated monkey model of Parkinson's disease.

Authors:  Elodie Durand; Odile Petit; Léon Tremblay; Cédric Zimmer; Véronique Sgambato-Faure; Carine Chassain; Marlène Laurent; Bruno Pereira; Céline Silberberg; Franck Durif
Journal:  Front Behav Neurosci       Date:  2015-02-26       Impact factor: 3.558

7.  PET quantification of [18F]MPPF in the canine brain using blood input and reference tissue modelling.

Authors:  Glenn Pauwelyn; Lise Vlerick; Robrecht Dockx; Jeroen Verhoeven; Andre Dobbeleir; Kathelijne Peremans; Ingeborg Goethals; Tim Bosmans; Christian Vanhove; Filip De Vos; Ingeborgh Polis
Journal:  PLoS One       Date:  2019-06-11       Impact factor: 3.240

8.  Effect of Citalopram on Emotion Processing in Humans: A Combined 5-HT1A [11C]CUMI-101 PET and Functional MRI Study.

Authors:  Sudhakar Selvaraj; Chris Walker; Danilo Arnone; Bo Cao; Paul Faulkner; Philip J Cowen; Jonathan P Roiser; Oliver Howes
Journal:  Neuropsychopharmacology       Date:  2017-08-04       Impact factor: 7.853

9.  Marmoset Serotonin 5-HT1A Receptor Mapping with a Biased Agonist PET Probe 18F-F13714: Comparison with an Antagonist Tracer 18F-MPPF in Awake and Anesthetized States.

Authors:  Chihiro Yokoyama; Aya Mawatari; Akihiro Kawasaki; Chiho Takeda; Kayo Onoe; Hisashi Doi; Adrian Newman-Tancredi; Luc Zimmer; Hirotaka Onoe
Journal:  Int J Neuropsychopharmacol       Date:  2016-12-30       Impact factor: 5.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.